AR122299A1 - Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents
Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílicoInfo
- Publication number
- AR122299A1 AR122299A1 ARP200102265A ARP200102265A AR122299A1 AR 122299 A1 AR122299 A1 AR 122299A1 AR P200102265 A ARP200102265 A AR P200102265A AR P200102265 A ARP200102265 A AR P200102265A AR 122299 A1 AR122299 A1 AR 122299A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxybenzoyl
- amino
- caprylic acid
- salt
- pcsk9 inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido EGF(A), y una sal del ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención además se refiere a los procesos para la preparación de tales composiciones, y su uso en la medicina. Reivindicación 1: Una composición farmacéutica que comprende a) 0,5 - 100 mg de derivado de EGF(A), b) 20 - 1000 mg, tal como 50 - 600 mg, de una sal del ácido N-(8-(2-hidroxibenzoil)amino)caprílico y en donde dicha sal del ácido N-(8-(2-hidroxibenzoil)amino)caprílico constituye al menos 90% p/p, tal como al menos 95% p/p de los excipientes de la composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19190506 | 2019-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122299A1 true AR122299A1 (es) | 2022-08-31 |
Family
ID=67551283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102265A AR122299A1 (es) | 2019-08-07 | 2020-08-07 | Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220323544A1 (es) |
| EP (1) | EP4009958A1 (es) |
| KR (1) | KR20220046565A (es) |
| CN (1) | CN114222581A (es) |
| AR (1) | AR122299A1 (es) |
| AU (1) | AU2020326265A1 (es) |
| BR (1) | BR112022000529A2 (es) |
| CA (1) | CA3144618A1 (es) |
| CO (1) | CO2022000575A2 (es) |
| IL (1) | IL289505A (es) |
| MX (1) | MX2022000889A (es) |
| PE (1) | PE20220486A1 (es) |
| TW (1) | TW202120118A (es) |
| WO (1) | WO2021023855A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023285580A1 (en) * | 2021-07-15 | 2023-01-19 | Novo Nordisk A/S | Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| WO2001092206A1 (en) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| ES2498519T3 (es) | 2006-09-07 | 2014-09-24 | F. Hoffmann-La Roche Ag | Un procedimiento para la fabricación de SNAC (SALCAPROZATO SÓDICO) |
| JP5902194B2 (ja) | 2010-12-16 | 2016-04-13 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物 |
| RU2014101501A (ru) | 2011-06-20 | 2015-07-27 | Дженентек, Инк. | Связывающие pcsk9 полипептиды и способы применения |
| ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
| JP6356660B2 (ja) * | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー／エス | 送達剤を含む組成物およびその調製 |
| RU2747877C2 (ru) | 2016-01-13 | 2021-05-17 | Ново Нордиск А/С | Аналоги эфр(а) с заместителями - жирными кислотами |
| WO2017220701A1 (en) * | 2016-06-24 | 2017-12-28 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cardiovascular disease |
| US20200165313A1 (en) | 2017-07-19 | 2020-05-28 | Novo Nordisk A/S | Egf(a) analogues, preparation, formulations and uses thereof |
-
2020
- 2020-08-07 WO PCT/EP2020/072227 patent/WO2021023855A1/en unknown
- 2020-08-07 US US17/628,697 patent/US20220323544A1/en not_active Abandoned
- 2020-08-07 BR BR112022000529A patent/BR112022000529A2/pt not_active Application Discontinuation
- 2020-08-07 CA CA3144618A patent/CA3144618A1/en not_active Withdrawn
- 2020-08-07 AR ARP200102265A patent/AR122299A1/es unknown
- 2020-08-07 EP EP20750288.1A patent/EP4009958A1/en not_active Withdrawn
- 2020-08-07 PE PE2022000111A patent/PE20220486A1/es unknown
- 2020-08-07 MX MX2022000889A patent/MX2022000889A/es unknown
- 2020-08-07 AU AU2020326265A patent/AU2020326265A1/en not_active Withdrawn
- 2020-08-07 CN CN202080055600.1A patent/CN114222581A/zh not_active Withdrawn
- 2020-08-07 TW TW109126752A patent/TW202120118A/zh unknown
- 2020-08-07 KR KR1020227004059A patent/KR20220046565A/ko unknown
-
2021
- 2021-12-29 IL IL289505A patent/IL289505A/en unknown
-
2022
- 2022-01-24 CO CONC2022/0000575A patent/CO2022000575A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022000529A2 (pt) | 2022-03-03 |
| US20220323544A1 (en) | 2022-10-13 |
| CO2022000575A2 (es) | 2022-04-29 |
| IL289505A (en) | 2022-02-01 |
| TW202120118A (zh) | 2021-06-01 |
| AU2020326265A1 (en) | 2022-02-03 |
| EP4009958A1 (en) | 2022-06-15 |
| PE20220486A1 (es) | 2022-04-04 |
| WO2021023855A1 (en) | 2021-02-11 |
| CA3144618A1 (en) | 2021-02-11 |
| KR20220046565A (ko) | 2022-04-14 |
| MX2022000889A (es) | 2022-02-14 |
| CN114222581A (zh) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009997A2 (es) | Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante | |
| CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| CO2022000578A2 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| CO2022005904A2 (es) | Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| AR122299A1 (es) | Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| CL2017003208A1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| CL2021000793A1 (es) | Inhibición de la proteasa 30 específica de la ubiquitina (usp30) | |
| CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| PH12021551086A1 (en) | Pharmaceutical formulations of cyclosporine analogs | |
| EA202192322A1 (ru) | Фармацевтические составы | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| BR112018070626A2 (pt) | formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição | |
| DOP2023000084A (es) | Formulación sólida | |
| AR122297A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| DOP2021000028A (es) | Formulaciones de dendrímeros | |
| CO2024000581A2 (es) | Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| UY39187A (es) | Composiciones y métodos para suministrar agentes farmacéuticamente activos | |
| CO2022011987A2 (es) | Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol | |
| AR110548A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
| AR127281A1 (es) | Dendrones peptídicos y métodos de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |